Related Experiment Videos
[Intravenous magnesium administration in bronchial asthma]
1Zürcher Hochgebirgsklinik, Clavadel-Davos.
Schweizerische Medizinische Wochenschrift
|November 18, 1989
Summary
Intravenous magnesium aspartate hydrochloride improved lung function in most asthma patients. This magnesium infusion significantly enhanced forced vital capacity, forced expiratory volume, and peak expiratory flow in asthmatic individuals.
Area of Science:
- Respiratory Medicine
- Clinical Pharmacology
Context:
- Asthma is a chronic respiratory disease characterized by airway inflammation and hyperreactivity.
- Current treatments aim to manage symptoms and prevent exacerbations, but novel therapeutic approaches are continually sought.
Purpose:
- To investigate the efficacy of intravenous magnesium aspartate hydrochloride (MgAHCl) in improving lung function parameters in hospitalized asthma patients.
- To assess the impact of MgAHCl on forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), and peak expiratory flow (PEF).
Summary:
- A study involving 17 asthmatic inpatients evaluated the effects of intravenous MgAHCl.
- Patients with initial FVC ≤ 90% showed significant improvements: FVC increased by 56-61% (p<0.01), FEV1 by 40-44% (p<0.02), and PEF by 45-56% (p<0.02).
- No significant changes in respiratory resistance were observed, but average serum magnesium levels increased during and after infusion.
Impact:
- Intravenous magnesium administration demonstrates potential as a valuable adjunct therapy for asthma management.
- MgAHCl may offer cardioprotective benefits and reduce bronchial hyperreactivity, contributing to improved outcomes in asthmatic patients.